$恒瑞医药(SH600276)$ Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma
| 发布于: | 雪球 | 转发：0 | 回复：0 | 喜欢：0 |
$恒瑞医药(SH600276)$ Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma